Human Genome Sciences (HGSI) resumes trading +10.5% AH after the FDA advisory panel approved...

|By:, SA News Editor

Human Genome Sciences (HGSI) resumes trading +10.5% AH after the FDA advisory panel approved Benlysta, the first new lupus drug in 50 years. While the FDA isn't bound by the panel's decision, it usually follows its recommendations. Target date for the final ruling: Dec. 9. (PR)